Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1385-1402 |
| Number of pages | 18 |
| Journal | Journal of Cachexia, Sarcopenia and Muscle |
| Volume | 13 |
| Issue number | 2 |
| Early online date | 22 Feb 2022 |
| DOIs | |
| Publication status | Published (in print/issue) - 22 Feb 2022 |
Bibliographical note
Funding Information:We thank the Human Cell Culture Platform of The Institute of Myology, and the ‘Plateforme Biopuces et Séquençage de l'IGBMC’. We thank Aswini Panigrahi for help with data upload. This work was financed by Target‐ALS (ViTAL consortium, PI: S Duguez), ARsLA (TEAM consortium, PI: S Duguez), European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for N. Ireland, Northern Ireland Public Health Agency (HSC R&D), and Ulster University (PI: T Bjourson). L.L.G. is a recipient from ArSLA. It was also partially supported by European Community's Health Seventh Framework Programme under grant agreement No. 259867 (Euro‐MOTOR), INSERM, Sorbonne University, and the AFM. All research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre ‐ the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The study was sponsored by APHP. Several samples (3) were obtained from an ongoing observational and prospective multicentric cohort (PULSE; Protocol 2013‐A00969‐36) sponsored by the University Hospital of Lille, conducted in 16 ALS expert centres from the clinical research networks in France (FILSLAN, ACT4ALS‐MND), approved from the CPP Nord Ouest‐IV Ethical Committee and registered in the ClinicalTrials.gov website (NCT02360891). We thank all the participants and their families for their cooperation. The authors are grateful for financial support of PULSE from the French ARSLA charity (), support from the French clinical research networks FILSLAN and ACT4ALS‐MND and the . Christine Tabuenca et Marie France Cazalère Fédération de la Recherche Clinique du CHU de Lille
Funding Information:
We thank the Human Cell Culture Platform of The Institute of Myology, and the ?Plateforme Biopuces et S?quen?age de l'IGBMC?. We thank Aswini Panigrahi for help with data upload. This work was financed by Target-ALS (ViTAL consortium, PI: S Duguez), ARsLA (TEAM consortium, PI: S Duguez), European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for N. Ireland, Northern Ireland Public Health Agency (HSC R&D), and Ulster University (PI: T Bjourson). L.L.G. is a recipient from ArSLA. It was also partially supported by European Community's Health Seventh Framework Programme under grant agreement No. 259867 (Euro-MOTOR), INSERM, Sorbonne University, and the AFM. All research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre - the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The study was sponsored by APHP. Several samples (3) were obtained from an ongoing observational and prospective multicentric cohort (PULSE; Protocol 2013-A00969-36) sponsored by the University Hospital of Lille, conducted in 16 ALS expert centres from the clinical research networks in France (FILSLAN, ACT4ALS-MND), approved from the CPP Nord Ouest-IV Ethical Committee and registered in the ClinicalTrials.gov website (NCT02360891). We thank all the participants and their families for their cooperation. The authors are grateful for financial support of PULSE from the French ARSLA charity (Christine Tabuenca et Marie France Cazal?re), support from the French clinical research networks FILSLAN and ACT4ALS-MND and the F?d?ration de la Recherche Clinique du CHU de Lille. The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.48
Publisher Copyright:
© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Funding
Funding Information: We thank the Human Cell Culture Platform of The Institute of Myology, and the ‘Plateforme Biopuces et Séquençage de l'IGBMC’. We thank Aswini Panigrahi for help with data upload. This work was financed by Target‐ALS (ViTAL consortium, PI: S Duguez), ARsLA (TEAM consortium, PI: S Duguez), European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for N. Ireland, Northern Ireland Public Health Agency (HSC R&D), and Ulster University (PI: T Bjourson). L.L.G. is a recipient from ArSLA. It was also partially supported by European Community's Health Seventh Framework Programme under grant agreement No. 259867 (Euro‐MOTOR), INSERM, Sorbonne University, and the AFM. All research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre ‐ the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The study was sponsored by APHP. Several samples (3) were obtained from an ongoing observational and prospective multicentric cohort (PULSE; Protocol 2013‐A00969‐36) sponsored by the University Hospital of Lille, conducted in 16 ALS expert centres from the clinical research networks in France (FILSLAN, ACT4ALS‐MND), approved from the CPP Nord Ouest‐IV Ethical Committee and registered in the ClinicalTrials.gov website (NCT02360891). We thank all the participants and their families for their cooperation. The authors are grateful for financial support of PULSE from the French ARSLA charity (), support from the French clinical research networks FILSLAN and ACT4ALS‐MND and the . Christine Tabuenca et Marie France Cazalère Fédération de la Recherche Clinique du CHU de Lille Funding Information: We thank the Human Cell Culture Platform of The Institute of Myology, and the ?Plateforme Biopuces et S?quen?age de l'IGBMC?. We thank Aswini Panigrahi for help with data upload. This work was financed by Target-ALS (ViTAL consortium, PI: S Duguez), ARsLA (TEAM consortium, PI: S Duguez), European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for N. Ireland, Northern Ireland Public Health Agency (HSC R&D), and Ulster University (PI: T Bjourson). L.L.G. is a recipient from ArSLA. It was also partially supported by European Community's Health Seventh Framework Programme under grant agreement No. 259867 (Euro-MOTOR), INSERM, Sorbonne University, and the AFM. All research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre - the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The study was sponsored by APHP. Several samples (3) were obtained from an ongoing observational and prospective multicentric cohort (PULSE; Protocol 2013-A00969-36) sponsored by the University Hospital of Lille, conducted in 16 ALS expert centres from the clinical research networks in France (FILSLAN, ACT4ALS-MND), approved from the CPP Nord Ouest-IV Ethical Committee and registered in the ClinicalTrials.gov website (NCT02360891). We thank all the participants and their families for their cooperation. The authors are grateful for financial support of PULSE from the French ARSLA charity (Christine Tabuenca et Marie France Cazal?re), support from the French clinical research networks FILSLAN and ACT4ALS-MND and the F?d?ration de la Recherche Clinique du CHU de Lille. The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.48 Publisher Copyright: © 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. © 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Keywords
- Secreted vesicles
- Cell-cell communication
- MND
- sporadic ALS
- Muscle Cells/metabolism
- Humans
- Proteomics
- Induced Pluripotent Stem Cells/metabolism
- Aged
- Amyotrophic Lateral Sclerosis/genetics
- Motor Neurons/metabolism
- Cell–cell communication
Fingerprint
Dive into the research topics of 'Muscle cells of sporadic amyotrophic lateral sclerosis patients secrete neurotoxic vesicles'. Together they form a unique fingerprint.Student theses
-
Identification of biomarkers to identify ALS subjects among patients affected by motor neuron disorders
Milla, V. (Author), Duddy, W. (Supervisor) & Duguez, S. (Supervisor), Oct 2022Student thesis: Doctoral Thesis
File -
Neurotoxicity of skeletal muscle extracellular vesicles in Amyotrophic Lateral Sclerosis (ALS): vesicle sub-type specificity, target cell type specificity, and mechanisms of uptake
Anakor, E. (Author), Duddy, W. (Supervisor) & Duguez, S. (Supervisor), May 2022Student thesis: Doctoral Thesis
File -
Secretion of neurotoxic vesicles by muscle cells of ALS patients
Le Gall, L. (Author), Duguez, S. (Supervisor) & Bjourson, A. (Supervisor), Sept 2019Student thesis: Doctoral Thesis
File